Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.3
-
Debt to Equity
0
-
Book Value
$13.2
-
EPS
$-7.5
-
Face value
--
-
Shares outstanding
3,041,830
7 Years Aggregate
CFO
$-24.36 Mln
EBITDA
$-28.46 Mln
Net Profit
$-32.08 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Painreform (PRFX)
| -70.0 | -11.8 | -28.8 | -88.1 | -87.7 | -80.6 | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Painreform (PRFX)
| -80.9 | -33.4 | -68.9 | -70.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Painreform (PRFX)
|
1.0 | 2.9 | 0.0 | -4.8 | -- | -93.3 | -- | 0.4 |
| 8.3 | 478.3 | 191.9 | 22.3 | 13.9 | 8.3 | 21.8 | 1.8 | |
| 12.7 | 163.4 | 11.9 | -20.2 | -176.1 | -50.9 | -- | 4.8 | |
| 5.1 | 103.0 | 0.0 | -31.5 | -- | -385.1 | -- | 19.2 | |
| 6.6 | 151.8 | 0.9 | -12.2 | -- | -196.5 | 0.1 | 0.9 |
Shareholding Pattern
View DetailsAbout Painreform (PRFX)
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in... cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel. Read more
-
Executive Chairman
Dr. Ehud Geller Ph.D.
-
Executive Chairman
Dr. Ehud Geller Ph.D.
-
Headquarters
Tel Aviv-Yafo
-
Website
FAQs for Painreform (PRFX)
What is the current share price of Painreform Ltd (PRFX) Today?
The share price of Painreform Ltd (PRFX) is $0.96 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Painreform Ltd (PRFX) has given a return of -87.73% in the last 3 years.
What is the current PB & PE ratio of Painreform Ltd (PRFX)?
Since, TTM earnings of Painreform Ltd (PRFX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.09 |
0.05 |
2024 |
-0.01 |
0.11 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Painreform Ltd (PRFX)?
The 52-week high and low of Painreform Ltd (PRFX) are Rs 8.05 and Rs 0.91 as of 31-Aug-2026.
What is the market cap of Painreform Ltd (PRFX)?
Painreform Ltd (PRFX) has a market capitalisation of $ 3 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Painreform Ltd (PRFX)?
Before investing in Painreform Ltd (PRFX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.